Marrow engraftment by allogeneic leukocytes in lethally irradiated dogs

Storb, R; Epstein, Robert B.; Ragde, Haakon; Bryant, J I; Thomas, E D

doi:10.1097/00007890-196808000-00026

Cited by 17 publications

(23 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the early 1960s, the term "blood stem cell" as a transplantable cell population was introduced. 6 BM rescue studies after autologous and allogeneic blood stem-cell transplantation into lethally irradiated large animals followed at Columbia University in Cooperstown, New York, 7 and at the University of Washington School of Medicine in Seattle, 8 but were not pursued at a clinical level because of the rarity of circulating stem cells at steady state compared with BM as a stem-cell source.…”

Section: Experimental Evidence Of Circulating Stem Cellsmentioning

confidence: 99%

Twenty-five years of peripheral blood stem cell transplantation

Körbling¹,

Freireich

2011

Blood

142

View full text Add to dashboard Cite

Section: Experimental Evidence Of Circulating Stem Cellsmentioning

confidence: 99%

Twenty-five years of peripheral blood stem cell transplantation

Körbling¹,

Freireich

2011

Blood

142

View full text Add to dashboard Cite

“…It has long been known that hematopoietic precursors circulate in the peripheral blood [1] and can be utilized for autologous or allogeneic transplantation [2,3]. In man, low, steady-state concentration of these cells has precluded harvesting of useful numbers within a practical number of apheresis procedures given the current technology [4].…”

Section: Introductionmentioning

confidence: 99%

Transplantation of Allogeneic Peripheral Blood Stem Cells Mobilized by Recombinant Human Granulocyte Colony Stimulating Factor

et al. 1996

View full text Add to dashboard Cite

Abstract. Recombinant G-CSF has been given to over 150 normal donors for the collection of allogeneic or syngeneic peripheral blood stem cells (PBSC). G-CSF was found to be well-tolerated with mild-moderate bone pain, edema and mild thrombocytopenia being the observed side effects. To date, approximately 90 unmodified primary PBSC transplants from HLA-identical related donors have been performed with engraftment that is, in general, considerably more rapid than marrow. Acute graftversus-host-disease (GVHD), grades II-IV occurred in 47% of patients and grades III-IV in 17%. Despite the infusion of one to two logs more T cells, these results are not remarkably different than would be expected with marrow transplantation. There have also been successful reports of using G-CSF mobilized allogeneic PBSC following second transplants for graft rejection or relapse. Allogeneic PBSC have been infused without reconditioning for correction of graft failure and unmodified or CD34 selected PBSC have also been given with marrow to augment the dose of hematopoietic cells. Further studies are needed to define the role of allogeneic PBSC for transplantation, refine PBSC mobilization and collection techniques and to evaluate the long-term effects of cytokines in normal donors.

show abstract

“…In vitro studies and animal experiments had shown that circulating peripheral blood stem cells were capable of fully repopulating a hematopoietic system. [5][6][7][8] Peripheral blood was not used clinically for two main reasons. The numbers of circulating stem cells were thought to be too low to be collected with reasonable methods for autologous and allogeneic HSCT.…”

mentioning

confidence: 99%

Change in stem cell source for hematopoietic stem cell transplantation (HSCT) in Europe: a report of the EBMT activity survey 2003

Gratwohl

Baldomero

Schmid

et al. 2005

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:This EBMT activity survey presents the status of hematopoietic stem cell transplantation (HSCT) in Europe 2003 and focuses on changes in stem cell source over the last decade. There were 21 028 first HSCT, 7091 allogeneic (34%), 13 937 autologous (66%) and 4179 additional re-or multiple transplants reported from 597 centers in 42 European countries in the year 2003. Main indications were leukemias (6613 (31%; 78% allogeneic)); lymphomas (11 571 (55%; 93% autologous)); solid tumors (1792 (9%; 92% autologous)) and nonmalignant disorders (898 (5%; 93% allogeneic)). In 1991, the vast majority of autologous and all allogeneic HSCT were still bone marrow (BM) transplants. Stem cell source changed rapidly to peripheral blood (PB) for autologous HSCT between 1992 and 1996. In 2003, 97% of autologous HSCT were PB derived. The change to PB for allogeneic HSCT followed 3 years later and occurred at a lower rate. In 2003, 65% of all allogeneic HSCT were PB derived. The change in stem cell source was not homogeneous. It was associated with donor type, main diagnosis, disease stage and it differed between European countries. In 2003, bone marrow remains a significant source of stem cells in some European countries for autologous HSCT and for nonmalignant disorders in allogeneic HSCT. Bone Marrow Transplantation (2005) 36, 575-590.

show abstract

Marrow engraftment by allogeneic leukocytes in lethally irradiated dogs

Cited by 17 publications

References 0 publications

Twenty-five years of peripheral blood stem cell transplantation

Twenty-five years of peripheral blood stem cell transplantation

Transplantation of Allogeneic Peripheral Blood Stem Cells Mobilized by Recombinant Human Granulocyte Colony Stimulating Factor

Change in stem cell source for hematopoietic stem cell transplantation (HSCT) in Europe: a report of the EBMT activity survey 2003

Contact Info

Product

Resources

About